PURPOSE: Conventional bioavailability testing of dosage forms based on plasma concentration-time graphs of two products in a two-period, crossover-design, is not applicable to topical treatment of intestinal segments. We introduce an isotope dual-label approach ((13)C- and (15)N(2)-urea) for colon drug delivery systems that can be performed in a one-day, non-invasive study-design. METHODS: Four healthy volunteers took an uncoated or a ColoPulse-capsule containing (13)C-urea and an uncoated capsule containing (15)N(2)-urea. In case of colon-release (13)C-urea is fermented and (13)C detected as breath (13)CO(2). Absorbed (13)C-urea and (15)N-urea are detected in urine. RESULTS: C and (15)N in urine released from uncoated capsules showed a ratio of 1.01 ± 0.06. The (13)C/(15)N-recovery ratio after intake of a ColoPulse-capsule was constant and lower >12 h post-dose (median 0.22, range 0.13-0.48). The (13)C/(15)N-ratio in a single urine sample at t ≥ 12 h predicted the 24 h non-fermented fraction (13)C of <26 %. Breath (13)CO(2) indicated delayed (>3 h) release and a fermented fraction (13)C >54 %. CONCLUSIONS: Breath and urine (13)C and (15)N data describe the release-profile and local bioavailability of a colon delivery device. This allows non-invasive bioavailability studies for evaluation of colon-specific drug delivery systems without radioactive exposure and with increased power and strongly reduced costs.
PURPOSE:Conventional bioavailability testing of dosage forms based on plasma concentration-time graphs of two products in a two-period, crossover-design, is not applicable to topical treatment of intestinal segments. We introduce an isotope dual-label approach ((13)C- and (15)N(2)-urea) for colon drug delivery systems that can be performed in a one-day, non-invasive study-design. METHODS: Four healthy volunteers took an uncoated or a ColoPulse-capsule containing (13)C-urea and an uncoated capsule containing (15)N(2)-urea. In case of colon-release (13)C-urea is fermented and (13)C detected as breath (13)CO(2). Absorbed (13)C-urea and (15)N-urea are detected in urine. RESULTS:C and (15)N in urine released from uncoated capsules showed a ratio of 1.01 ± 0.06. The (13)C/(15)N-recovery ratio after intake of a ColoPulse-capsule was constant and lower >12 h post-dose (median 0.22, range 0.13-0.48). The (13)C/(15)N-ratio in a single urine sample at t ≥ 12 h predicted the 24 h non-fermented fraction (13)C of <26 %. Breath (13)CO(2) indicated delayed (>3 h) release and a fermented fraction (13)C >54 %. CONCLUSIONS: Breath and urine (13)C and (15)N data describe the release-profile and local bioavailability of a colon delivery device. This allows non-invasive bioavailability studies for evaluation of colon-specific drug delivery systems without radioactive exposure and with increased power and strongly reduced costs.
Authors: M Brunner; S Ziegler; A F D Di Stefano; P Dehghanyar; K Kletter; M Tschurlovits; R Villa; R Bozzella; G Celasco; L Moro; A Rusca; R Dudczak; M Müller Journal: Br J Clin Pharmacol Date: 2006-01 Impact factor: 4.335
Authors: M Brunner; E Lackner; P S Exler; H C Fluiter; K Kletter; M Tschurlovits; R Dudczak; H-G Eichler; M Müller Journal: Aliment Pharmacol Ther Date: 2006-01-01 Impact factor: 8.171
Authors: R C A Schellekens; F Stellaard; G G Olsder; H J Woerdenbag; H W Frijlink; J G W Kosterink Journal: J Control Release Date: 2010-05-31 Impact factor: 9.776
Authors: Nancy E Martin; Kathryn R Collison; Louis L Martin; Sarah Tardif; Ian Wilding; Heather Wray; Jeffrey S Barrett Journal: J Clin Pharmacol Date: 2003-05 Impact factor: 3.126
Authors: R C A Schellekens; G G Olsder; S M C H Langenberg; T Boer; H J Woerdenbag; H W Frijlink; J G W Kosterink; F Stellaard Journal: Br J Pharmacol Date: 2009-09 Impact factor: 8.739
Authors: R C A Schellekens; F Stellaard; D Mitrovic; F E Stuurman; J G W Kosterink; H W Frijlink Journal: J Control Release Date: 2008-08-23 Impact factor: 9.776
Authors: Jacoba M Maurer; Reinout C A Schellekens; Hèlen M van Rieke; Christoph Wanke; Ventzeslav Iordanov; Frans Stellaard; Klaus D Wutzke; Gerard Dijkstra; Margot van der Zee; Herman J Woerdenbag; Henderik W Frijlink; Jos G W Kosterink Journal: PLoS One Date: 2015-07-15 Impact factor: 3.240